Moreover, Vorinostat treatment reduced levels of Arginase and many other genes implicated in M-MDSC-mediated immune suppression within the CD45+CD11b+ NBL tumor-infiltrating myeloid cells. The gene discussed is PTPRC; the disease is neoplasm.